Acil Serviste Anjiyoödem Yönetimi

Yazarlar

Efşan Gürbüz Yontar

Özet

Anjiyoödem, mikrovasküler permeabilite artışı sonucu subkütanöz ve submukozal dokularda gelişen çukurlaşmayan ödemle karakterize, anafilaksi ve havayolu obstrüksiyonu riski nedeniyle ölümcül seyredebilen acil bir dermatolojik tablodur. Etiyopatogenezine göre histaminerjik, bradikininerjik, histaminerjik veya bradikininerjik olmayan ve idiyopatik anjiyoödem şeklinde sınıflandırılmaktadır. Histaminerjik tipte klinik tablo etkenle teması takiben hızla ortaya çıkıp ürtiker ve kaşıntı ile seyredebilirken; bradikininerjik grupta (herediter, edinsel C1 inhibitörü eksikliği, ADE inhibitörü ilişkili) semptomlar daha yavaş gelişir, daha uzun sürer, ürtiker eşlik etmez ve gastrointestinal sistem tutulumu akut batını taklit eden şiddetli abdominal ağrılara yol açabilir. Laboratuvar değerlendirmesinde C1 inhibitörü düzeyi ve disfonksiyonu, C4, C1q ve serum triptaz seviyeleri ile abdominal USG/BT gibi tetkikler kullanılır. Acil müdahalede hayati bulguların stabilizasyonu, yakın monitörizasyon ve havayolu güvenliğinin sağlanması kritik önem taşır; laringeal tutulumda zor entübasyon tecrübesi olan hekimlerce erken entübasyon veya cerrahi havayolu uygulanmalıdır. Tedavide histaminerjik formlar H1 antihistaminikler, kortikosteroidler ve epinefrine yanıt verirken; bradikininerjik formlarda bu ilaçlar etkisizdir ve C1 inhibitör konsantreleri, ikatibant, ekallantid veya taze donmuş plazma verilmelidir. Ishoo evre 3-4 veya ilerleyici ödemi olan hastalar yoğun bakıma sevk edilmelidir.

Angioedema is an emergency dermatological condition characterized by non-pitting edema developing in subcutaneous and submucosal tissues due to increased microvascular permeability, which can be fatal owing to the risks of anaphylaxis and airway obstruction. According to its etiopathogenesis, it is classified into histaminergic, bradykininergic, non-histaminergic/non-bradykininergic, and idiopathic angioedema. In the histaminergic type, clinical signs appear rapidly following exposure to triggers and may be accompanied by urticaria and pruritus; whereas in the bradykininergic group (hereditary, acquired C1 inhibitor deficiency, ACE inhibitor-related), symptoms develop more slowly, persist longer, lack associated urticaria, and gastrointestinal involvement can cause severe abdominal pain mimicking an acute abdomen. Laboratory evaluation utilizes C1 inhibitor level and function, C4, C1q, and serum tryptase levels, along with imaging modalities such as abdominal USG/CT. In emergency management, stabilizing vital signs, close monitoring, and securing the airway are of critical importance; in cases of laryngeal involvement, early intubation by physicians experienced in difficult airways or surgical airway interventions may be required. Regarding medical treatment, histaminergic forms respond to H1 antihistamines, corticosteroids, and epinephrine; however, these agents are ineffective in bradykininergic forms, requiring C1 inhibitor concentrates, icatibant, ecallantide, or fresh frozen plasma. Patients presenting with Ishoo stage 3-4 or progressive edema should be transferred to the intensive care unit.

Referanslar

Freiman A, Borsuk D, Sasseville D. Dermatologic emergencies.CMAJ. 2005;173:1317-9.

Wang E, Lim BL, Than KY. Dermatological conditions presenting at an emergency department in Singapore. Singapore Med J. 2009;50:881-884.

Alpalhão M, Uva L, Soromenho G, et al. Dermatological emergencies: one-year data analysis of 8,620 patients from the largest Portuguese tertiary teaching hospital. Eur J Dermatol. 2016;26:460-464.

Martínez-Martínez ML, Escario-Travesedo E, Rodríguez-Vázquez M, et al. [Dermatology consultations in an emergency department prior to establishment of emergency dermatology cover]. Actas Dermosifiliogr. 2011;102:39-47.

Vleeming W, van Amsterdam JGC, Stricker BHCh, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf 1998;18:171–88.

Moellman JJ, Bernstein JA, Lindsell C, et al. A consensus parameter for the evaluation and management of angioedema in the emergency department. Acad Emerg Med. 2014;21(4):46984.

Bork K. An evidence based therapeutic approach to hereditary and acquired angioedema. Curr Opin Allergy Clin Immunol. 2014;14(4):354-62.

Kim SJ, Brooks JC, Sheikh J, et al. Angioedema deaths in the United States, 1979-2010. Ann Allergy Asthma Immunol. 2014;113(6):630-4.

Bernstein JA, Moellman J. Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int J Emerg Med. 2012;5(1):39.

Pedrosa, M., Prieto-García, A., Sala-Cunill, A., Spanish Group for the Study of Bradykinin-Mediated Angioedema (SGBA) and the Spanish Committee of Cutaneous Allergy (CCA), Spanish Group for the Study of Bradykinin-Mediated Angioedema (SGBA):, Caballero, T., ... & Villareal, O. (2014). Management of angioedema without urticaria in the emergency department. Annals of medicine, 46(8), 607-618.

Busse, P. J., & Smith, T. (2017). Histaminergic angioedema. Immunology and Allergy Clinics, 37(3), 467-481.

Hacard, F., Nosbaum, A., Bensaid, B., Nicolas, J. F., Augey, F., Goujon, C., & Bérard, F. (2014). Histaminergic angioedema and chronic urticaria. Presse Medicale (Paris, France: 1983), 44(1), 37-42.

Zuraw, B. L. (2008). Hereditary angioedema. New England Journal of Medicine, 359(10), 1027-1036.

Lunn M, Banta E. Ecallantide for the treatment of hereditary angiodema in adults. Clin Med Insights Cardiol 2011;5:49–54.

Blanch A, Roche O, L ó pez-Granados E, Font á n G, L ó pez-Trascasa M. Detection of C1 inhibitor (SERPING1/C1NH) mutations in exon 8 in patients with hereditary angioedema: evidence for 10 novel mutations. Hum Mutation. 2002 ; 20 : 405 – 6.

Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1- inhibitor activity in women. Lancet 2000;356:213–7.

Bafunno V, Firinu D, D’Apolito M, Cordisco G, Loffredo S, Leccese A, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol 2018;141:1009–17.

Bork K, Wulff K, Steinmüller-Magin L, Braenne I, Staubach-Renz P, Witzke G, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy 2018;73:442–50.

Binkley KE, Davis A III. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000;106:546–50.

Castelli R, Deliliers D, Zingale LC, Pogliani E, Cicardi M. Lymphoproliferative disease and acquired C1 inhibitor defi ciency . Haematologica. 2007; 92: 716– 18.

Barilla-LaBarca M, Gioff re D, Zanichelli A, Cicardi M, Atkinson JP. Acquired C1 esterase inhibitor defi ciency in two patients presenting with a lupus-like syndrome and anticardiolipin antibodies . Arthritis Rheum. 2002; 47: 223– 6.

Farkas H, Szongoth M, B é ly M, Varga L, Fekete B, Kar á di I, et al. Angiooedema due to acquired defi ciency of C1-esterase inhibitör associated with leucocytoclastic vasculitis. Acta Derm Venereol. 2001 ; 81 : 298 – 300 .

Farkas H, Csepregi A, Nemes á nszky E. Acquired angioedema associated with chronic hepatitis C. J Allergy Clin Immunol. 1999; 103: 711– 12.

Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency andangioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009;15:69–78.

Maurer M, Magerl M, Ansotegui I, Aygören-Pürsün E, Betschel S, Bork K, et al. The international WAO/EAACI guideline for the management of hereditary angioedema- the 2017 revision and update. Allergy 2018. https://doi.org/10.1111/all. 13384. [Epub ahead of print].

Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy. 2007;62(8):842-56.

Bernstein JA. Update on angioedema: evaluation, diagnosis, and treatment. Allergy Asthma Proc. 2011;32(6):408-12.

Banerji A, Clark S, Blanda M, et al. Multicenter study of patients with angiotensin-converting enzyme inhibitor induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol. 2008;100(4):327-32.

Bluestein HM, Hoover TA, Banerji AS, et al. Angiotensinconverting enzyme inhibitor-induced angioedema in a community hospital emergency department. Ann Allergy Asthma Immunol. 2009;103(6):502-7.

Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance . Ann Allergy Asthma Immunol. 2007 ; 99 : 13 – 21.

Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician 2003;68:1781–91.

Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014 ;69(5):602-16.

Kaplan AP. Angioedema World Allergy Organ J 2008;1:103–13.

Bucher MC, Petkovic T, Helbling A, Steiner UC. Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials. Clin Transl Allergy 2017;317:27.

Cugno M, Tedeschi A, Nussberger J. Bradykinin in idiopathic non-histaminergic angioedema. Clin Exp Allergy 2017;47:139–40.

Agostoni A, Ayg ö ren-P ü rs ü n E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond . J Allergy Clin Immunol . 2004 ; 114(3 Suppl) :S51– 131.

Carreer FM. Th e C1 inhibitor defi ciency. A review. Eur J Clin Chem Clin Biochem. 1992; 30: 793– 807.

Farkas H, Harmat G, F á y A, Fekete B, Kar á di I, Visy B, et al. Erythema marginatum preceding an acute oedematous attack of hereditary angioneurotic oedema. Acta Derm Venereol. 2001; 81: 376– 7.

Temino VM, Stokes Peebles RS Jr. The spectrum and treatment of angioedema. Am J Med 2008;121:282–6.

Caballero T , B aeza M L, C abañ a s R , C ampos A , C imbollek S , G ó mez-Traseira C, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Investig Allergol Clin Immunol. 2011; 21: 422– 3.

Pedrosa M , C aballero T , G ó m ez-Traseira C , O lveira A , L ó p ez-Serrano MC, L ó pez-Serrano C . Usefulness of abdominal ultrasonography in the follow-up of patients with hereditary C1-inhibitor defi ciency . Ann Allergy Asthma Immunol. 2009; 102: 483– 6.

Sadeghi N, Van Daele D, Hainaux B, Engelholm L, Michel O. Hereditary angio-edema involving the gastrointestinal tract: CT fi ndings. Eur Radiol. 2001; 11: 99– 101.

Nzeako U C. D iagnosis and management of angioedema with abdominal involvement: a gastroenterology perspective . World J Gastroenterol. 2010 ; 16 : 4913.

Craig T, Pursun EA, Bork K, et al. WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J. 2012;5(12):182-99.

Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24.

Lang DM, Aberer W, Bernstein JA, et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol. 2012;109(6):395-402.

Markovic SN, Inwards DJ, Phyliky RP. Acquired C1 esterase inhibitör deficiency. Ann Intern Med. 2000;133(10):839.

Li H, Busse P, Lumry WR, et al. Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema. J Allergy Clin Immunol Pract. 2015;3(2):200-5.

Bork K. Angioedema. Immunol Allergy Clin North Am. 2014;34(1):23-31.

Wilkerson RG. Angioedema in the emergency department: an evidencebased review . Emerg Med Pract. 2012 ; 14 : 1 – 21 .

Sabroe RA, Black AK. Angiotensin-converting enzyme (ACE) inhibitors and angiooedema. Br J Dermatol 1997;136:153–8.

Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692-7.

Bork K. Recurrent angioedema and the threat of asphyxiation. Dtsch Arztebl Int. 2010;107(23):408-14.

Palmer M, Rosenbaum S. Clinical practice guideline: initial evaluation and management of patients presenting with acute urticaria or angioedema. American Academy of Emergency Medicine. Available at: http://www.aaem.org/education/urticaria_angioedema. php. Published July 10, 2006. Accessed August 1, 2011.

Bernstein JA, Cremonsei P, Hoffman TK, et al. Angioedema in the emergency department: a practical guide to differential diagnosis and management. Int J Emerg Med. 2017;10(1):15.

Kramer A, Müller D, Pförtner R, et al. Fibreoptic vs videolaryngoscopic (C-MAC(®) D-BLADE) nasal awake intubation under local anaesthesia. Anaesthesia. 2015;70(4):400-6.

Simmons ST, Schleich AR. Airway regional anesthesia for awake fiberoptic intubation. Reg Anesth Pain Med. 2002;27(2):180-92.

Long, B. J., Koyfman, A., & Gottlieb, M. (2019). Evaluation and management of angioedema in the emergency department. Western Journal of Emergency Medicine, 20(4), 587.

Ishoo, E., Shah, U. K., Grillone, G. A., Stram, J. R., & Fuleihan, N. S. (1999). Predicting airway risk in angioedema: staging system based on presentation. Otolaryngology—Head and Neck Surgery, 121(3), 263-268.

James C, Bernstein JA. Current and future therapies for the treatment of histamine-induced angioedema. Expert Opin Pharmacother. 2017;18(3):253-62.

Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med. 2000;36(5):462-8.

Rosenberg, D. L., Viswanathan, R. K., & Mathur, S. K. (2019). Response to H1 Antihistamine Therapy in Idiopathic Angioedema. Journal of Allergy and Clinical Immunology, 143(2), AB45.

Cicardi M, Bellis P, Bertazzoni G, Cancian M, Chiesa M, Cremonesi P, et al. Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts. Intern Emerg Med 2014;9:85–92.

Johnston SL, Unsworth J, Gompels MM. Adrenaline given outside the context of life threatening allergic reactions. BMJ. 2003;326(7389):589-90.

ECC Committee, Subcommittee and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005;112(24 Suppl):IV1-203.

Banerji A. Current treatment of hereditary angioedema: an update on clinical studies. Allergy Asthma Proc 2010;31:398–406.

Cruden NLM, Newby DE. Therapeutic potential of icatibant (HOE-140, JE-049). Expert Opin Pharmacother 2008;9:2383–90.

Bergamaschini L, Cicardi M. Recent advances in the use of C1 inhibitor as a therapeutic agent. Mol Immunol 2003;40:155-8.

Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007;119(6):1497-503.

Betschel S, Badiou J, Binkley K, Hébert J, Kanani A, Keith P, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2014;10(1):50.

Jose J, Zacharias J, Craig T. Review of select practice parameters, evidence-based treatment algorithms, and international guidelines for hereditary angioedema. Clin Rev Allergy Immunol. 2016; 51(2):193-206.

Wentzel, N., Panieri, A., Ayazi, M., Ntshalintshali, S. D., Pourpak, Z., Hawarden, D., ... & Peter, J. (2019). Fresh frozen plasma for on-demand hereditary angioedema treatment in South Africa and Iran. World Allergy Organization Journal, 12(9), 100049.

Sobash, P. T., Vedala, K., & Kamoga, G. R. (2021). Utilization of Tranexamic Acid for Recurrent Angioedema after ARB Discontinuation: A Case report and Review of the Literature. Archives of Clinical and Medical Case Reports, 5(1), 204-209

Sayfalar

281-294

Gelecek

25 Ocak 2022

Lisans

Lisans